Cooper Companies delivered strong Q4 2024 results with revenue reaching $1,018.4 million, up 10% year-over-year and 7% organically. Gross margin improved to 67% from 65% last year, while operating margin expanded to 19% from 15%. GAAP diluted EPS increased 38% to $0.58, and non-GAAP EPS rose 19% to $1.04.CooperVision revenue grew 9% to $676.4 million, with strong performance across all categories and regions. CooperSurgical revenue increased 12% to $342.0 million, driven by 15% growth in fertility solutions. The company generated free cash flow of $128.2 million after capital expenditures of $139.9 million.For fiscal 2025, Cooper projects total revenue of $4.08-4.16 billion, representing organic growth of 6-8%. The guidance includes CooperVision revenue growth of 6.5-8.5% and CooperSurgical growth of 4-6%. Non-GAAP EPS is expected to reach $3.92-4.02.

Cooper Companies delivered strong Q4 2024 results with revenue reaching $1,018.4 million, up 10% year-over-year and 7% organically. Gross margin improved to 67% from 65% last year, while operating margin expanded to 19% from 15%. GAAP diluted EPS increased 38% to $0.58, and non-GAAP EPS rose 19% to $1.04.CooperVision revenue grew 9% to $676.4 million, with strong performance across all categories and regions. CooperSurgical revenue increased 12% to $342.0 million, driven by 15% growth in fertility solutions. The company generated free cash flow of $128.2 million after capital expenditures of $139.9 million.For fiscal 2025, Cooper projects total revenue of $4.08-4.16 billion, representing organic growth of 6-8%. The guidance includes CooperVision revenue growth of 6.5-8.5% and CooperSurgical growth of 4-6%. Non-GAAP EPS is expected to reach $3.92-4.02.